ReviewNarra J2026
Biomarkers for diagnosis, disease progression, and therapeutic response in psoriasis vulgaris: A mini-review.
Review in Narra J, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis vulgaris is a chronic immune-mediated inflammatory disease with substantial clinical, psychosocial, and public health impact. Despite advances in therapeutic options, disease management continues to rely predominantly on clinical assessment, which remains limited in its ability to detect early disease, quantify subclinical inflammation, monitor disease progression, and anticipate long-term outcomes. These limitations are further compounded by marked interindividual heterogeneity in disease course, systemic inflammatory burden, comorbidity risk, and treatment response. Although a growing body of research has identified numerous candidate biomarkers related to genetic susceptibility, epidermal pathology, immune activation, and systemic inflammation, their clinical relevance and integration into routine practice remain unclear. A comprehensive synthesis that bridges molecular biomarkers with clinically meaningful applications is therefore needed. This review critically examines the current landscape of biomarkers in psoriasis vulgaris and explores their potential roles in diagnosis, assessment of disease progression, and prediction of therapeutic response. This review discusses genetic biomarkers associated with disease susceptibility and immune pathway regulation, tissue- associated biomarkers reflecting epidermal dysfunction and local inflammatory activity, and soluble biomarkers indicative of systemic inflammation and metabolic dysregulation. By organizing existing evidence across these biomarker domains, this review seeks to highlight conceptual frameworks, unresolved challenges, and future directions for biomarker-informed psoriasis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.